NL300251I2 - Thiënyl-, furyl-, pyrrolyl- en bifenyl-sulfonamiden en derivaten voor het moduleren van de endotheline-activiteit. - Google Patents
Thiënyl-, furyl-, pyrrolyl- en bifenyl-sulfonamiden en derivaten voor het moduleren van de endotheline-activiteit.Info
- Publication number
- NL300251I2 NL300251I2 NL300251C NL300251C NL300251I2 NL 300251 I2 NL300251 I2 NL 300251I2 NL 300251 C NL300251 C NL 300251C NL 300251 C NL300251 C NL 300251C NL 300251 I2 NL300251 I2 NL 300251I2
- Authority
- NL
- Netherlands
- Prior art keywords
- pyrrolyl
- furyl
- thienyl
- derivatives
- modulating
- Prior art date
Links
- 108050009340 Endothelin Proteins 0.000 title abstract 3
- 102000002045 Endothelin Human genes 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title 1
- 125000002541 furyl group Chemical group 0.000 title 1
- 125000000168 pyrrolyl group Chemical group 0.000 title 1
- 125000001544 thienyl group Chemical group 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- 102000010180 Endothelin receptor Human genes 0.000 abstract 1
- 108050001739 Endothelin receptor Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41707595A | 1995-04-04 | 1995-04-04 | |
| US41619995A | 1995-04-04 | 1995-04-04 | |
| US08/477,223 US5594021A (en) | 1993-05-20 | 1995-06-06 | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| PCT/US1996/004759 WO1996031492A1 (en) | 1995-04-04 | 1996-04-04 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300251I1 NL300251I1 (nl) | 2007-02-01 |
| NL300251I2 true NL300251I2 (nl) | 2007-03-01 |
Family
ID=27411089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300251C NL300251I2 (nl) | 1995-04-04 | 2006-12-13 | Thiënyl-, furyl-, pyrrolyl- en bifenyl-sulfonamiden en derivaten voor het moduleren van de endotheline-activiteit. |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP1048657A1 (Direct) |
| JP (3) | JP3233642B2 (Direct) |
| KR (2) | KR100359396B1 (Direct) |
| CN (1) | CN1130355C (Direct) |
| AT (1) | ATE243203T1 (Direct) |
| AU (1) | AU711968B2 (Direct) |
| CA (1) | CA2217169C (Direct) |
| CZ (1) | CZ299246B6 (Direct) |
| DE (2) | DE69628740T2 (Direct) |
| DK (1) | DK0819125T3 (Direct) |
| EA (2) | EA199900808A1 (Direct) |
| EE (1) | EE9700251A (Direct) |
| ES (1) | ES2201181T3 (Direct) |
| FI (1) | FI973879A0 (Direct) |
| HU (1) | HUP9802034A3 (Direct) |
| NL (1) | NL300251I2 (Direct) |
| NO (1) | NO315607B1 (Direct) |
| NZ (2) | NZ306734A (Direct) |
| OA (1) | OA10621A (Direct) |
| PL (1) | PL186854B1 (Direct) |
| PT (1) | PT819125E (Direct) |
| TR (1) | TR199701096T1 (Direct) |
| TW (1) | TW492966B (Direct) |
| WO (1) | WO1996031492A1 (Direct) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2001523218A (ja) | 1996-02-20 | 2001-11-20 | ブリストル―マイヤーズ・スクイブ・カンパニー | ビフェニルイソキサゾール・スルホンアミドの製造法 |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| WO1998033781A1 (en) * | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| EA003993B1 (ru) * | 1997-04-28 | 2003-12-25 | Инсизив Фармасьютикэлз Инк. | Сульфонамиды для лечения заболеваний, связанных с эндотелином |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| IL140622A0 (en) * | 1998-07-06 | 2002-02-10 | Bristol Myers Squibb Co | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
| HU228111B1 (en) | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| EP1209149B9 (en) * | 1999-08-06 | 2011-08-31 | Takeda Pharmaceutical Company Limited | Substituted aromatic-ring compounds, process for producing the same, and use |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU2456701A (en) * | 1999-12-31 | 2001-07-16 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
| AU2464301A (en) * | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| EP1533311B1 (en) * | 1999-12-31 | 2007-04-25 | Encysive Pharmaceuticals, Inc | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| GB0000625D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| DE60142914D1 (de) * | 2000-09-18 | 2010-10-07 | Toa Eiyo Ltd | N-substituierte benzothiophensulfonamid-derivate |
| US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| EP1347051A4 (en) * | 2000-12-26 | 2004-05-26 | Genox Research Inc | METHOD FOR EXAMINING AN ALLERGIC DISEASE |
| DE60333351D1 (de) * | 2002-03-15 | 2010-08-26 | Toa Eiyo Ltd | N-substituiertes benzothiophensulfonamidderivat |
| CA2494962C (en) | 2002-08-09 | 2011-06-14 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1534268A4 (en) * | 2002-08-09 | 2006-11-02 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
| SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
| SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
| SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
| SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
| SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
| SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
| KR101325519B1 (ko) * | 2004-10-14 | 2013-11-08 | 애보트 게엠베하 운트 콤파니 카게 | 도파민 ｄ3 수용체의 조절에 반응하는 장애를 치료하기에적합한 아릴설포닐메틸 또는 아릴설폰아미드 치환된 방향족화합물 |
| CN101730694A (zh) | 2007-04-10 | 2010-06-09 | 奥斯拜客斯制药有限公司 | 用于治疗高血压的取代的氘富集的噻吩 |
| WO2008154484A1 (en) | 2007-06-08 | 2008-12-18 | Mannkind Corporation | Ire-1a inhibitors |
| AR089838A1 (es) | 2012-01-31 | 2014-09-17 | Eisai R&D Man Co Ltd | Derivados de sitaxetan |
| CN107652246B (zh) * | 2017-09-25 | 2020-08-25 | 江苏乾元生物科技有限公司 | 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法 |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| PL3986890T3 (pl) | 2019-06-18 | 2024-03-11 | Pfizer Inc. | Pochodne benzizoksazolosulfonamidu |
| EP3831940A1 (en) * | 2019-12-05 | 2021-06-09 | Danmarks Tekniske Universitet | Small molecule inhibitors of crispr-cas associated activity |
| CN112663077B (zh) * | 2021-01-11 | 2022-07-01 | 陕西师范大学 | 一种苯并磺内酰胺类化合物的电化学制备方法 |
| IL306095A (en) | 2021-06-22 | 2023-11-01 | Alchemedicine Inc | Compound, endothelin-A receptor antagonist, and pharmaceutical preparation |
| KR20240035402A (ko) | 2021-07-09 | 2024-03-15 | 바이코어 파마 아베 | 신규의 선택적 안지오텐신 ii 화합물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660383A (en) * | 1968-08-14 | 1972-05-02 | Shionogi & Co | Production of iodoisoxazole compounds |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| TW224462B (Direct) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
-
1996
- 1996-04-04 NZ NZ306734A patent/NZ306734A/en unknown
- 1996-04-04 JP JP53052496A patent/JP3233642B2/ja not_active Expired - Lifetime
- 1996-04-04 AU AU55367/96A patent/AU711968B2/en not_active Ceased
- 1996-04-04 CN CN96193973A patent/CN1130355C/zh not_active Expired - Fee Related
- 1996-04-04 ES ES96912600T patent/ES2201181T3/es not_active Expired - Lifetime
- 1996-04-04 TR TR97/01096T patent/TR199701096T1/xx unknown
- 1996-04-04 CA CA002217169A patent/CA2217169C/en not_active Expired - Fee Related
- 1996-04-04 PT PT96912600T patent/PT819125E/pt unknown
- 1996-04-04 DE DE69628740T patent/DE69628740T2/de not_active Expired - Lifetime
- 1996-04-04 DK DK96912600T patent/DK0819125T3/da active
- 1996-04-04 EE EE9700251A patent/EE9700251A/xx unknown
- 1996-04-04 DE DE1996628740 patent/DE122006000068I1/de active Pending
- 1996-04-04 KR KR1019970707078A patent/KR100359396B1/ko not_active Expired - Fee Related
- 1996-04-04 EA EA199900808A patent/EA199900808A1/ru unknown
- 1996-04-04 CZ CZ0311697A patent/CZ299246B6/cs not_active IP Right Cessation
- 1996-04-04 AT AT96912600T patent/ATE243203T1/de active
- 1996-04-04 EA EA199700208A patent/EA007107B1/ru not_active IP Right Cessation
- 1996-04-04 EP EP00113076A patent/EP1048657A1/en not_active Withdrawn
- 1996-04-04 HU HU9802034A patent/HUP9802034A3/hu unknown
- 1996-04-04 WO PCT/US1996/004759 patent/WO1996031492A1/en not_active Ceased
- 1996-04-04 EP EP96912600A patent/EP0819125B1/en not_active Expired - Lifetime
- 1996-04-04 KR KR1019997007068A patent/KR100359397B1/ko not_active Expired - Fee Related
- 1996-04-04 NZ NZ500282A patent/NZ500282A/xx unknown
- 1996-10-04 TW TW085112218A patent/TW492966B/zh not_active IP Right Cessation
-
1997
- 1997-10-01 PL PL96322707A patent/PL186854B1/pl not_active IP Right Cessation
- 1997-10-02 OA OA70095A patent/OA10621A/en unknown
- 1997-10-03 NO NO19974577A patent/NO315607B1/no not_active IP Right Cessation
- 1997-10-03 FI FI973879A patent/FI973879A0/fi not_active Application Discontinuation
-
2001
- 2001-06-06 JP JP2001171692A patent/JP3527217B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-10 JP JP2003318261A patent/JP2004043495A/ja active Pending
-
2006
- 2006-12-13 NL NL300251C patent/NL300251I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300251I1 (nl) | Thiënyl-, furyl-,pyrrolyl- en bifenyl-sulfonamiden en derivaten voor het moduleren van de endotheline-activiteit. | |
| FI950309A0 (fi) | Proliiniamidijohdannaisia | |
| NO20001045L (no) | Nye cycliske tetrapeptidderivater og medisinsk anvendelse derav | |
| DK0891325T3 (da) | Para-substituerede phenylpropansyrederivater som integrinantagonister | |
| ATE174592T1 (de) | Sulfonamide und derivate zur modulierung der endothelin aktivitat | |
| EP0638071A1 (en) | HETEROCYCLIC CARBONIC ACID DERIVATIVES THAT CAN BIND TO RARE RECEPTORS. | |
| GB0215650D0 (en) | Bisarylsufonamide compounds | |
| DK0976748T3 (da) | Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet | |
| EP1486207A3 (en) | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | |
| ATE156116T1 (de) | Auf aromatischen sulfonamiden basierende hydroxamsäurederivate | |
| BR9609744A (pt) | Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2 | |
| ZA934997B (en) | Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives | |
| DE60129442D1 (de) | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten | |
| IE45051L (en) | Quinazolines | |
| EP1026162A4 (en) | ANTI-RHUMATISMAL AGENT | |
| DE69627519D1 (de) | Sesquiterpen-derivate mit antiviraler aktivität | |
| ATE286892T1 (de) | Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität | |
| EP0913393A3 (en) | Arylacetic amide derivative or salt thereof, and pharmaceutical comprising it | |
| ATE94168T1 (de) | Peptide. | |
| WO1997029077A1 (fr) | Derives amides substitues | |
| ES2195309T3 (es) | Derivados de tetrahidrofurano. | |
| RU96115369A (ru) | Пара-оксифенилуксусная кислота и/или ее соль в качестве средства для снижения отпугивающего действия инсектицидов |